Drug Aimed at Inflammation May Lower Risk of Heart Disease and Cancer
The anti-inflammatory drug canakinumab "..can reduce the risk of heart attacks and strokes, and possibly lung cancer, in people who have already had one heart attack and are at high risk for another..."
And it only costs $200k per year.
canakinumab is owned by Novartis. And the study was paid for by... Novartis! Amazing.
I'm sure there's no other anti-inflammatory drug cheaper than $200k a year that could help
The anti-inflammatory drug canakinumab "..can reduce the risk of heart attacks and strokes, and possibly lung cancer, in people who have already had one heart attack and are at high risk for another..."
And it only costs $200k per year.
canakinumab is owned by Novartis. And the study was paid for by... Novartis! Amazing.
I'm sure there's no other anti-inflammatory drug cheaper than $200k a year that could help